LGALS1 and lymphoma: Increased endogenous expression of Galectin-1 was observed to protect K562 chronic myelogenous leukemia cells against adriamycin and imatinib, and in a mouse lymphoma model, Galectin-1 inhibited CD20 mAb-dependent, macrophage-mediated cell killing [8, 9].